MedTrace Logo

Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

NCT06713798 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-03-23

No results posted yet for this study

Summary

This study encompasses multicenter open-label, phase II trials.

Patients will be dispatched into 2 cohorts:

* Cohort A: Patients naïve from systemic treatment will be randomized according to two treatment modalities: atezolizumab + tiragolumab (arm A1) versus atezolizumab monotherapy (arm A2).

43 patients are to be included in each arm.
* Cohort B: Patients with previous exposure to ICI will be treated with the combination of atezolizumab and tiragolumab.

29 patients are to be included in this cohort.

Conditions

Interventions

DRUG

Atezolizumab 1200 mg IV

atezolizumab (intravenous 1200mg Q3W)

DRUG

Tiragolumab 600 mg IV

Tiragolumab (intravenous 600mg Q3W)

Sponsors & Collaborators

  • Roche Global Development

    collaborator OTHER

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-30
Primary Completion
2025-09-15
Completion
2025-09-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06713798 on ClinicalTrials.gov